Roche

Roche Receives FDA Approval Of Label Expansion For Ventana Pd-l1 (Sp263) Assay To Identify Patients With Locally Advanced And Metastatic Non-small Cell Lung Cancer Eligible For Libtayo

The VENTANA PD-L1 (SP263) Assay helps determine which patients with non-small cell lung cancer (NSCLC) may be eligible for treatment with Libtayo monotherapy1 based on the results of the Phase III EMP...

Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics

New agreement expands activities to include a wide-range of companion diagnostics, including tissue and blood-based biomarkers, sequencing and digital pathology. Collaboration builds on commitment to ...

Roche announces Brad Moore as president and CEO of Roche Diagnostics North America

Roche have announced the appointment of Brad Moore as president and CEO of Roche Diagnostics North America, effective January 1, 2023. Moore currently serves as senior vice president, Core Lab and Poi...

Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Developed as a predictive biomarker, the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. The new test ident...

Roche introduces the Navify brand for its digital health solutions at HLTH 2022

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. The navify portfolio uses digital solutions, analytics and data science to p...